OncoGeneX Pharmaceuticals, Inc., a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer, has just announced it has signed an initial agreement contract with Teva Pharmaceutical Industries Ltd. to reclaim rights to custirsen, an experimental drug currently undergoing Phase III clinical testing as a potential treatment for lung